Verrica announces YCANTH receives new chemical entity status

Verrica Pharmaceuticals announced that the Company’s lead product, YCANTH, has received New Chemical Entity Status and a listing in the Orange Book from the U.S. Food and Drug Administration, providing a minimum five years of regulatory exclusivity. “We could not be more pleased to announce YCANTH has been granted NCE Status by the FDA,” said Ted White, Verrica’s President and Chief Executive Officer. “Today’s announcement represents the continued execution of our Company’s comprehensive intellectual property strategy to maximize the patent and regulatory protections surrounding YCANTH and further underscores the product’s innovation and intrinsic value in the dermatology market. While NCE status will provide YCANTH with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond.”